Septerna, Inc. | MedPath

Novo Nordisk and Septerna Partner on $2.2 Billion Deal to Develop Oral Obesity Treatments

11 days ago

• Novo Nordisk and Septerna have formed a $2.2 billion collaboration to develop oral small molecule therapies targeting GLP-1, GIP, and glucagon receptors for obesity and cardiometabolic diseases. • The partnership combines Novo Nordisk's expertise in metabolic diseases with Septerna's proprietary Native Complex Platform™ technology for G protein-coupled receptor (GPCR) drug discovery, addressing a significant untapped opportunity in GPCR therapeutics. • Septerna will receive over $200 million in upfront and near-term payments, with both companies jointly conducting research through candidate selection before Novo Nordisk assumes global development responsibilities.

GSK's Linerixibat Shows Significant Improvement in Cholestatic Pruritus for Primary Biliary Cholangitis Patients

16 days ago

• GSK's phase III GLISTEN trial demonstrates linerixibat significantly improves cholestatic pruritus (relentless itch) in patients with primary biliary cholangitis, addressing a major quality of life concern. • The late-breaking results were presented at the European Association for the Study of the Liver (EASL) Congress 2025, highlighting the potential for a new treatment option for this challenging symptom. • Primary biliary cholangitis is a chronic autoimmune liver disease that primarily affects women, with pruritus being one of the most debilitating symptoms impacting daily functioning and quality of life.

Septerna Halts Phase 1 Trial of SEP-786 for Hypoparathyroidism Due to Safety Concerns

3 months ago

• Septerna discontinues Phase 1 trial of SEP-786, an oral PTH1R agonist for hypoparathyroidism, following two cases of severe elevated unconjugated bilirubin in multiple-ascending dose study. • Despite early signs of target engagement with increased serum calcium and decreased PTH levels, the company pivots to advancing alternative PTH1R agonist candidates with distinct chemical structures. • Company maintains strong financial position with $440.1 million in resources, supporting operations through 2027 while advancing multiple programs including SEP-631 for mast cell diseases.